FDA Approves First-in-Class Drug for Migraine Prevention FDA Approves First-in-Class Drug for Migraine Prevention

The human monoclonal antibody erenumab has become the first anti-calcitonin-gene-related peptide (CGRP) treatment to receive FDA approval for the prevention of migraine.FDA Approvals
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Neurology & Neurosurgery News Alert Source Type: news